Market Overview

UPDATE: Stifel Nicolaus Upgrades Penn Virginia Corporation to Buy on Attractive Entry Point

Related PVA
Penn Virginia Corporation Announces Borrowing Base Increase To $500M And Financial Liquidity In Excess Of $620M
Kite Pharmaceuticals Releases Positive Non-Hodgkin's Lymphoma Result; iKang Healthcare Disappoints

Stifel Nicolaus raised its rating on Penn Virginia Corporation (NYSE: PVA) from Hold to Buy and established a $6.50 price target.

Stifel Nicolaus noted, "While PVA is not one of our highest quality buys, we believe the stock is attractive for investors looking for small cap energy names that should be turning a corner. … [T]he initial 2013 guidance, which was released with 3Q results, has reduced the guidance risk that was present in the name, given that quarterly production had been declining sequentially with the two rig program.With a more attractive entry point, better positioned balance sheet, and initial 2013 guidance reducing 2013 CF estimate risk, we think it makes sense to be long the stock again. Production should begin growing sequentially in 1Q13, as the impact of the third rig is felt, and we believe that this growth will be the key driver for the stock price."

Penn Virginia Corporation closed at $4.62 on Monday.

Latest Ratings for PVA

DateFirmActionFromTo
Dec 2014BarclaysMaintainsEqual-weight
Dec 2014Imperial CapitalMaintainsOutperform
Nov 2014Credit SuisseMaintainsOutperform

View More Analyst Ratings for PVA
View the Latest Analyst Ratings

Posted-In: Stifel NicolausAnalyst Color Upgrades Intraday Update Analyst Ratings

 

Related Articles (PVA)

Around the Web, We're Loving...

Get Benzinga's Newsletters